Celcuity (CELC) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $3.27B and a free-cash-flow yield of -4.9%. Nama's AI scorecard rates it Sell, 3.4 out of 10. On 12-month momentum it ranks in the lagging band of its market.
AI scorecard
Sell · 3.4/10
Negative, at the mild end of Sell. As of Nov 7, 2026.
Momentum
Lagging · -11.4% over 12 months ex. last
Second-worst fifth of its market on the past year's move.
Shariah screen
Not Shariah Compliant
At least one of the three ratios or the industry test failed.
Off its high
-55.8%
How far the last close sits under the highest price of the past five years.
Market cap
$3.27B
Trailing P/E
—
Price / book
—
Price / sales
—
FCF yield
-4.9%
Dividend yield
—
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Revenue growth (YoY)
—
Revenue growth (3-yr annual)
—
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
0.1
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
CELC earnings
Next report: Mar 24, 2027 (Q4 2026, EPS estimate -$1.18).
Beat the EPS estimate in 4 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q3 2026
Nov 5, 2026
-$1.21
-$1.53
+20.9%
—
Q2 2026
Aug 13, 2026
-$1.07
-$1.08
+0.9%
$0
Q1 2026
May 14, 2026
-$0.86
-$0.89
+3.4%
$0
Q4 2025
Mar 25, 2026
-$0.73
-$1.01
+27.7%
$0
CELC analyst price target
Median target $151.00 from 13 analysts, ranging $130.00 – $177.00.
Nama's AI scorecard currently rates Celcuity Sell (3.4 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does CELC report earnings?
Celcuity's next scheduled report is on Mar 24, 2027. Analysts expect EPS of -$1.18.
What is the CELC price target?
The median analyst price target from 13 analysts is $151.00, with a range of $130.00 – $177.00.
Is CELC Shariah compliant?
Nama's AAOIFI-style screen reads Celcuity as Not Shariah Compliant. At least one of the three ratios or the industry test failed.